期刊
CANCER RESEARCH
卷 78, 期 1, 页码 103-114出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-1462
关键词
-
类别
资金
- Cancer Center Support Grant [P30 CA013330]
- National Cancer Institute [R01 CA135061-01A1, R01CA136854-01A1]
- Breast Cancer Research Foundation
The Akt pathway is a well-known promoter of tumormalignancy. Akt3 is expressed as two alternatively spliced variants, one of which lacks the key regulatory serine 472 phosphorylation site. Whereas the function of full-length Akt3 isoform (Akt3/thornS472) is well-characterized, that of Akt3/-S472 isoformremains unknown. Despite being expressed at a substantially lower level than Akt3/thornS472 in triple-negative breast cancer cells, specific ablation of Akt3/-S472 enhanced, whereas overexpression, suppressed mammary tumor growth, consistent with a significant association with patient survival duration relative to Akt3/thornS472. These effects were due to striking induction of apoptosis, which was mediated by Bim upregulation, leading to conformational activation of Bax and caspase-3 processing. Bim accumulation was caused by marked endocytosis of EGF receptors with concomitant ERK attenuation, which stabilizes BIM. These findings demonstrate an unexpected function of an endogenously expressed Akt isoform in promoting, as opposed to suppressing, apoptosis, underscoring that Akt iso-forms may exert dissonant functions in malignancy. (C) 2017 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据